Latest News for: cv6

Edit

CV6 Therapeutics Announces Initiation of Patient Dosing in Phase 1a Clinical Trial Evaluating the Investigational First-In-Class, Specific dUTPase Inhibitor CV6-168

Pharmiweb 16 Aug 2024
Study will assess the safety, pharmacokinetic and pharmacodynamic profiles and anti-tumor activity for CV6-168 in the treatment of multiple solid cancers, including colon, gastric, breast, ovarian, lung, and other solid tumors.
Edit

CV6 Therapeutics Announces Initiation Of Patient Dosing In Phase 1A Clinical Trial Evaluating The Investigational ...

MENA FN 15 Aug 2024
(MENAFN - GlobeNewsWire - Nasdaq) – Study will assess the safety, pharmacokinetic and pharmacodynamic profiles and anti-tumor activity for CV6-168 in the treatment of multiple solid cancers, ... .
Edit

CV6 Therapeutics Receives MHRA Approval For Novel Cancer Therapy Phase 1A Clinical Trial

MENA FN 14 Dec 2023
(MENAFN - GlobeNewsWire - Nasdaq) BELFAST, United Kingdom, Dec. 14, 2023 (GLOBE NEWSWIRE) -- CV6 Therapeutics ('CV6'), a drug development biotechnology company that specializes in innovative small ... .
Edit

CV6 Therapeutics to commence UK-wide clinical trial for first of its kind anti-cancer drug (Queen's University Belfast)

Public Technologies 14 Dec 2023
) CV6 Therapeutics to commence UK-wide clinical trial for first of its kind anti-cancer drug ... CV6 Therapeutics, based at the Patrick G ... CV6-168 will be one of the first novel cancer drugs to be developed and trialed in Northern Ireland.
Edit

Belfast-based CV6 Therapeutics to invest €9.3m in new anti-cancer drug

The Irish Times 02 Nov 2022
Robert Ladner, founder and CEO of CV6 Therapeutics; Ian Greer, QUB president and vice chancellor; Brian McCaul, chief executive at QUBIS ... We are grateful for the continued support of Invest NI and our investors,” said Dr Robert Ladner, CEO of CV6.
Edit

CV6 Therapeutics Secures $9.2m to Progress Novel Cancer Drug to Phase 1a Trial

Pharmiweb 02 Nov 2022
Belfast, UK, 2 November 2022 – CV6 Therapeutics (‘CV6’), a drug development ... CV6 is developing CV6-168, a novel, first-in-class DNA uracilation agent that selectively targets the enzyme dUTPase.
  • 1

Most Viewed

×